NCT02396511View on ClinicalTrials.gov

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Choriocarcinoma
Interventions
BIOLOGICAL

TRC105

weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops

BIOLOGICAL

Bevacizumab

Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops

Trial Locations (1)

02215

Dana-Farber Cancer Insititue, Boston

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT02396511 - TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma | Biotech Hunter | Biotech Hunter